Our Science
Zymeworks is utilizing our experience and capabilities to generate a product pipeline of novel, multifunctional therapeutics
Revolutionary technologies engineering fit-for-purpose biotherapeutics
Our fully integrated R&D engine is powered by our proprietary platforms and driven by our team of world-class researchers who have a proven ability to discover, develop, and collaborate with partners to commercialize our novel agents globally.
Our pipeline of novel multifunctional therapeutics is supported by our clinically validated, best-in-class antibody–drug conjugates (ADCs) and multispecific antibody therapeutics (MSATs) technology platforms.
ADC technology harnesses the power of potent payloads and the specificity of antibodies to selectively deliver small molecule drugs to tumors. We are applying our proprietary ADC payloads and other drug conjugate technologies in the development of diverse therapeutic candidates. These technologies can also be paired with our Azymetric™ technology platform to create next generation bispecific ADCs.
Multispecific antibody therapeutics enable engagement of independent targets expressed on the same cell or on different cell populations, engaging biology and affording therapeutic opportunities, not feasible with single-target antibodies or antibody combinations. Our clinically validated technologies harness the flexibility of our proprietary Azymetric™ technology as a foundation to solve biological challenges.
Science that’s focused on transforming areas of high unmet medical need
As a team and an organization, we thrive on scientific challenges and strive to deliver transformational therapies for patients with difficult-to-treat cancers and other serious diseases.
